Source:http://linkedlifedata.com/resource/pubmed/id/10800630
Switch to
Predicate | Object |
---|---|
rdf:type | |
lifeskim:mentions | |
pubmed:issue |
4
|
pubmed:dateCreated |
2000-6-9
|
pubmed:abstractText |
Two different oral tetrazepam (CAS 10379-14-3) formulations (Tetrazepam-ratiopharm film-coated tablets as test preparation and tablets of a reference preparation marketed in France) were investigated in 20 healthy volunteers in order to prove bioequivalence between these preparations. A single 50 mg oral dose was given according to a randomised two-way crossover design in the fasted state. Blood samples for determination of tetrazepam plasma concentrations were collected at pre-defined time points up to 96 h following drug administration. A washout period of 14 days separated both treatment periods. Tetrazepam plasma concentrations were determined by means of a validated LC-MS/MS method. Values of 3873.08 ngh/ml (test preparation) and 3930.69 ngh/ml (reference preparation) for the parameter AUC0-infinity demonstrate an nearly identical extent of drug absorption. Maximum concentrations (Cmax) of 482.08 ng/ml and 465.14 ng/ml were achieved for test and reference preparation. Time to reach maximum plasma concentration (tmax) was 1.39 hours for both preparations. Cmax and AUC0-infinity-values were tested parametrically by an analysis of variance (ANOVA). Bioequivalence was concluded if the 90% confidence intervals of the T/R-ratios were in the range of 80%-125% for AUC0-infinity and 70%-143% for Cmax. Based on the results obtained in this study, bioequivalence between the test and the reference preparation was demonstrated.
|
pubmed:commentsCorrections | |
pubmed:language |
eng
|
pubmed:journal | |
pubmed:citationSubset |
IM
|
pubmed:chemical | |
pubmed:status |
MEDLINE
|
pubmed:month |
Apr
|
pubmed:issn |
0004-4172
|
pubmed:author | |
pubmed:issnType |
Print
|
pubmed:volume |
50
|
pubmed:owner |
NLM
|
pubmed:authorsComplete |
Y
|
pubmed:pagination |
328-32
|
pubmed:dateRevised |
2008-11-21
|
pubmed:meshHeading |
pubmed-meshheading:10800630-Administration, Oral,
pubmed-meshheading:10800630-Adult,
pubmed-meshheading:10800630-Anti-Anxiety Agents,
pubmed-meshheading:10800630-Area Under Curve,
pubmed-meshheading:10800630-Benzodiazepines,
pubmed-meshheading:10800630-Biological Availability,
pubmed-meshheading:10800630-Calibration,
pubmed-meshheading:10800630-Chromatography, Liquid,
pubmed-meshheading:10800630-Cross-Over Studies,
pubmed-meshheading:10800630-Drug Stability,
pubmed-meshheading:10800630-Female,
pubmed-meshheading:10800630-Humans,
pubmed-meshheading:10800630-Male,
pubmed-meshheading:10800630-Mass Spectrometry,
pubmed-meshheading:10800630-Quality Control,
pubmed-meshheading:10800630-Tablets, Enteric-Coated
|
pubmed:year |
2000
|
pubmed:articleTitle |
Bioavailability investigation of two different oral formulations of Tetrazepam.
|
pubmed:affiliation |
Pharmakin GmbH, Gesellschaft für Pharmakokinetik, Ulm, Germany. ursugeis@pharmakin.de
|
pubmed:publicationType |
Journal Article,
Clinical Trial,
Comparative Study,
Randomized Controlled Trial
|